BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE

被引：0
|
作者：
Hernandez, L. G. [1 ]
Paly, V [1 ]
Li, S. [2 ]
Khanduri, P. [3 ]
Asfaw, A. A. [4 ]
Zou, D. [5 ]
机构：
[1] Takeda Pharmaceut America Inc, Lexington, MA USA
[2] Evidera, Toronto, ON, Canada
[3] Evidera, Waltham, MA USA
[4] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
[5] Evidera, San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE267
引用
收藏
页码：S106 / S106
页数：1
相关论文
共 50 条
  • [1] Budget impact analysis of introducing fruquintinib for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and biologics in the United States from the payer perspective
    Paly, Victoria Federico
    Li, Shujun
    Khanduri, Pratishtha
    Asfaw, Alemseged Ayele
    Zou, Denise
    Hernandez, Luis
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 1076 - 1085
  • [2] Fruquintinib for previously treated metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (08): : E388 - E388
  • [3] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Shelbaya, A.
    Yang, J.
    VALUE IN HEALTH, 2020, 23 : S15 - S15
  • [4] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Al Taie, A.
    Shelbaya, A.
    VALUE IN HEALTH, 2020, 23 : S16 - S17
  • [5] Fruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments
    Quesada, Stanislas
    Chatelet, Chloe
    BULLETIN DU CANCER, 2024, 111 (12) : 1084 - 1085
  • [6] BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE
    Bui, C. N.
    O'Day, K.
    Flanders, S.
    Oestreicher, N.
    Francis, P.
    Posta, L.
    Popelar, B.
    Tang, H.
    Balk, M.
    VALUE IN HEALTH, 2015, 18 (03) : A196 - A196
  • [7] BUDGET IMPACT ANALYSIS OF ENZALUTAMIDE FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER FROM A US PAYER PERSPECTIVE
    O'Day, Ken
    Bui, Cat N.
    Flanders, Scott
    Oestreicher, Nina
    Francis, Peter
    Posta, Linda
    Popelar, Breanna
    Tang, Hong
    Balk, Mark
    JOURNAL OF UROLOGY, 2015, 193 (04): : E934 - E935
  • [8] Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
    Chaplin, Stephen
    van Stiphout, Joris
    Chen, Anna
    Li, Edward
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (11): : 1226 - 1238
  • [9] BUDGET IMPACT OF INTRODUCING SECUKINUMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS FROM THE PRIVATE PAYER PERSPECTIVE IN BRAZIL
    Tozato, C.
    Huerta, C.
    Suzuki, C.
    Lopes, N.
    VALUE IN HEALTH, 2018, 21 : S291 - S291
  • [10] The budget impact of introducing pembrolizumab to the formulary in the United States for previously treated PD-L1 positive advanced cervical cancer
    Nwankwo, C.
    Hirst, A.
    Kondic, A. G.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 202 - 203
12345